Christopher Cline's most recent trade in Travere Therapeutics Inc was a trade of 27,473 Common Stock done at an average price of $62.0 . Disclosure was reported to the exchange on Sept. 15, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 62.00 per share. | 15 Sep 2026 | 27,473 | 110,543 (0%) | 0% | 62.0 | 1,703,241 | Common Stock |
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 62.61 per share. | 15 Sep 2026 | 20,735 | 89,808 (0%) | 0% | 62.6 | 1,298,175 | Common Stock |
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | 15 Sep 2026 | 20,000 | 0 | - | - | Employee stock option (right to buy) | ||
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.44 per share. | 15 Sep 2026 | 20,000 | 138,016 (0%) | 0% | 17.4 | 348,800 | Common Stock |
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 63.69 per share. | 15 Sep 2026 | 1,900 | 87,908 (0%) | 0% | 63.7 | 121,004 | Common Stock |
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 65.31 per share. | 15 Sep 2026 | 400 | 87,508 (0%) | 0% | 65.3 | 26,124 | Common Stock |
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 66.37 per share. | 02 Sep 2026 | 642 | 118,016 (0%) | 0% | 66.4 | 42,610 | Common Stock |
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | 04 May 2026 | 8,500 | 8,500 | - | - | Performance-based restricted stock units | ||
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2026 | 4,250 | 121,149 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | 04 May 2026 | 4,250 | 4,250 | - | - | Performance-based restricted stock units | ||
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 46.65 per share. | 04 May 2026 | 2,181 | 118,968 (0%) | 0% | 46.7 | 101,744 | Common Stock |
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 43.95 per share. | 04 May 2026 | 310 | 118,658 (0%) | 0% | 44.0 | 13,625 | Common Stock |
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Apr 2026 | 14,000 | 125,226 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 41.93 per share. | 13 Apr 2026 | 7,239 | 117,913 (0%) | 0% | 41.9 | 303,523 | Common Stock |
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 42.61 per share. | 13 Apr 2026 | 1,014 | 116,899 (0%) | 0% | 42.6 | 43,207 | Common Stock |
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 28.85 per share. | 13 Apr 2026 | 65 | 125,161 (0%) | 0% | 28.8 | 1,875 | Common Stock |
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 41.11 per share. | 13 Apr 2026 | 9 | 125,152 (0%) | 0% | 41.1 | 370 | Common Stock |
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 32.14 per share. | 04 Feb 2026 | 1,635 | 111,336 (0%) | 0% | 32.1 | 52,549 | Common Stock |
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 32.90 per share. | 04 Feb 2026 | 110 | 111,226 (0%) | 0% | 32.9 | 3,619 | Common Stock |
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | 31 Jan 2026 | 75,000 | 75,000 | - | - | Employee stock option (right to buy) | ||
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2026 | 28,130 | 120,213 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 32.12 per share. | 31 Jan 2026 | 7,242 | 112,971 (0%) | 0% | 32.1 | 232,613 | Common Stock |
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 35.01 per share. | 01 Dec 2025 | 20,000 | 92,083 (0%) | 0% | 35.0 | 700,202 | Common Stock |
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.23 per share. | 01 Dec 2025 | 20,000 | 112,083 (0%) | 0% | 16.2 | 324,600 | Common Stock |
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | 01 Dec 2025 | 20,000 | 0 | - | - | Employee stock option (right to buy) | ||
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 18.20 per share. | 03 Sep 2025 | 454 | 92,202 (0%) | 0% | 18.2 | 8,263 | Common Stock |
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 19.71 per share. | 03 Sep 2025 | 119 | 92,083 (0%) | 0% | 19.7 | 2,345 | Common Stock |
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 17.31 per share. | 27 Aug 2025 | 470 | 92,656 (0%) | 0% | 17.3 | 8,136 | Common Stock |
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2025 | 4,920 | 94,910 (0%) | 0% | - | Common Stock | |
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | 02 May 2025 | 4,920 | 4,920 | - | - | Performance-based restricted stock units | ||
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 21.05 per share. | 02 May 2025 | 1,784 | 93,126 (0%) | 0% | 21.0 | 37,553 | Common Stock |
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 13.15 per share. | 11 Apr 2025 | 48 | 89,990 (0%) | 0% | 13.1 | 631 | Common Stock |
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | 31 Jan 2025 | 58,000 | 58,000 | - | - | Employee stock option (right to buy) | ||
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 21,500 | 95,230 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 20.12 per share. | 31 Jan 2025 | 5,192 | 90,038 (0%) | 0% | 20.1 | 104,463 | Common Stock |
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 18.94 per share. | 22 Jan 2025 | 865 | 73,730 (0%) | 0% | 18.9 | 16,384 | Common Stock |
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Sep 2024 | 6,750 | 77,085 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 11.52 per share. | 05 Sep 2024 | 2,490 | 74,595 (0%) | 0% | 11.5 | 28,685 | Common Stock |
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 9.51 per share. | 04 Sep 2024 | 514 | 70,335 (0%) | 0% | 9.5 | 4,888 | Common Stock |
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 6.74 per share. | 11 Apr 2024 | 54 | 70,849 (0%) | 0% | 6.7 | 364 | Common Stock |
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | 31 Jan 2024 | 65,000 | 65,000 | - | - | Employee stock option (right to buy) | ||
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 25,000 | 74,721 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 8.53 per share. | 31 Jan 2024 | 3,818 | 70,903 (0%) | 0% | 8.5 | 32,573 | Common Stock |
| Travere Therapeutics Inc | Mr. Christopher Cline | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 9.07 per share. | 23 Jan 2024 | 853 | 49,721 (0%) | 0% | 9.1 | 7,735 | Common Stock |
| Travere Therapeutics Inc | Mr. Christopher Cline | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 14.71 per share. | 05 Sep 2023 | 457 | 50,574 (0%) | 0% | 14.7 | 6,723 | - |
| Travere Therapeutics Inc | Mr. Christopher Cline | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 16.59 per share. | 10 May 2023 | 455 | 51,031 (0%) | 0% | 16.6 | 7,548 | Common Stock |
| Travere Therapeutics Inc | Mr. Christopher Cline | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.49 per share. | 11 Apr 2023 | 47 | 51,486 (0%) | 0% | 21.5 | 1,010 | Common Stock |
| Travere Therapeutics Inc | Mr. Christopher Cline | Chief Financial Officer | 31 Jan 2023 | 54,500 | 54,500 | - | - | Employee stock option (right to buy) | ||
| Travere Therapeutics Inc | Mr. Christopher Cline | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 20,250 | 53,121 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Mr. Christopher Cline | Chief Financial Officer | 31 Jan 2023 | 6,750 | 6,750 | - | - | Performance-based restricted stock units | ||
| Travere Therapeutics Inc | Mr. Christopher Cline | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.75 per share. | 31 Jan 2023 | 1,588 | 51,533 (0%) | 0% | 21.8 | 34,542 | Common Stock |
| Travere Therapeutics Inc | Mr. Christopher Cline | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.90 per share. | 24 Jan 2023 | 852 | 32,871 (0%) | 0% | 21.9 | 18,663 | Common Stock |
| Travere Therapeutics Inc | Mr. Christopher Cline | Chief Financial Officer | 01 Sep 2022 | 48,000 | 48,000 | - | - | Employee Stock option (right to buy) | ||
| Travere Therapeutics Inc | Mr. Christopher Cline | Chief Financial Officer | 01 Sep 2022 | 9,840 | 9,840 | - | - | Performance-based restricted stock units | ||
| Travere Therapeutics Inc | Mr. Christopher Cline | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 5,000 | 33,723 (0%) | 0% | 0 | Common Stock |